Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.18M Buy
746,635
+66,592
+10% +$237K ﹤0.01% 6519
2026
Q2
$2.78M Buy
+680,043
New +$2.25M ﹤0.01% 5832
2025
Q3
– Sell
-92,361
Closed -$264K – 13678
2025
Q2
$301K Buy
+92,361
New +$232K ﹤0.01% 9818
2023
Q3
– Sell
-25
Closed -$83 – 14820
2023
Q2
$119 Hold
25
– – ﹤0.01% 14217
2023
Q1
$163 Sell
25
-1,231
-98% -$12.5K ﹤0.01% 14559
2022
Q4
$13.9K Buy
+1,256
New +$12.7K ﹤0.01% 13414
2022
Q3
– Sell
-9,167
Closed -$61.8K – 13277
2022
Q2
$55K Buy
+9,167
New +$120K ﹤0.01% 11870
2021
Q4
– Sell
-13,509
Closed -$975K – 14443
2021
Q3
$1.25M Buy
+13,509
New +$1.76M ﹤0.01% 7554

Other funds holding NRXP

Citadel Advisors's NRXP Position: Q3 2026 in Review

Citadel Advisors increased its NRX Pharmaceuticals (NRXP) stake by 9.8% in Q3 2026, buying an estimated $237K and bringing the position to 746,635 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #6519.

Citadel Advisors first reported a position in NRXP in Q3 2021 and has held it in 8 quarters since. The position peaked at $2.78M in Q2 2026. 50 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

  • Citadel Advisors held 746,635 shares of NRX Pharmaceuticals worth $2.18M as of Q3 2026.
  • Citadel Advisors bought 66,592 NRX Pharmaceuticals shares in Q3 2026, an estimated $237K.
  • NRX Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6519 holding.
  • Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • Citadel Advisors's NRX Pharmaceuticals position peaked at $2.78M in Q2 2026.
  • 50 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.